Cerebrotech Medical Systems on Jan. 4 earned FDA clearance for the Cerebrotech Visor, a diagnostic device for patients undergoing neurological assessment.
The portable, noninvasive device assesses fluid volume differences between the brain's right and left hemispheres in 30 seconds. The device can aid clinicians in diagnosing numerous brain pathologies like stroke or brain swelling, since many neurological conditions result in asymmetrical fluid volumes between the brain hemispheres.
"We understand the challenges facing medical professionals who need to quickly assess patients with neurologic symptoms," said Cerebrotech Medical Systems CEO Mitch Levinson. "Utilizing the vast amount of data captured by our proprietary Cerebrotech Visor, our mission is to develop unique algorithms that can help physicians to better detect and diagnose a wide range of neurological conditions, improving outcomes for patients while reducing overall healthcare costs."
More articles on supply chain:
Celgene to acquire Impact Biomedicines for up to $7B
AdvaMed TV ads call on Congress to end device tax: 4 things to know
FDA OKs expanded use of Amgen's bone drug: 4 things to know